HealthPhoto: News18Controversy Over SMA Drug Risdiplam Distribution in Kerala
A controversy has emerged in Kerala regarding the distribution of risdiplam, a drug for spinal muscular atrophy (SMA). Parents found labels stating "clinical trial only," raising concerns about the drug's safety and approval status. This has sparked political debate, with opposition leaders demanding transparency about the distribution process and the drug's suitability for patients with this genetic condition.
News18·




